TP53 and colon adenocarcinoma: To test whether the established signature can be used for prognosis prediction in COAD with TP53 wild-type, the prognostic significance of our signature were also evaluated in COAD samples with TP53 wild type, including 352 TP53 wild-type samples in the GSE39582 and 253 samples with TP53 wild-type in the combined RNA-seq cohort.